Korlym Clinical Development
This article was originally published in Pharmaceutical Approvals Monthly
A timeline chronicling the development history of Corcept’s mifepristone for Cushing’s syndrome.
You may also be interested in...
The $9.7bn acquisition hinges on the small interfering RNA inclisiran, but an ongoing cardiovascular outcomes trial, manufacturing hurdles, and reimbursement challenges provide subjects for concern.
The latest oncology development news and highlights from our US FDA Performance Tracker.
Rigorous planning and a multidisciplinary team including database experts and healthcare specialists with local knowledge are vital to effective real-world evidence, white paper shows.